TheScreener - Bavarian Nordic A/S (BAVA) BAVARIAN NORDIC sees an upgrade to Slightly Positive due to a better fundamental star rating

Report

TheScreener

EUR 13.20 For Business Accounts Only

BAVARIAN NORDIC sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of BAVARIAN NORDIC (DK), a company active in the Biotechnology industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 3 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date March 18, 2022, the closing price was DKK 168.35 and its potential was estimated at DKK 225.09.

19/03/2022 1 EN

Underlying

Bavarian Nordic A/S

Bavarian Nordic is engaged in the development and production of vaccines. Co. offers products based on its technology MVA-BN, a vaccine against smallpox and HIV/AIDS, breast and prostate cancer. Co.'s marketed products includes IMVAMUNE, a smallpox vaccine. Co.'s products also are comprised of PROSTVAC which is for the treatment of prostate cancer; Anthrax vaccine is for the treatment of biological threats; MVA-BN PRO is for the treatment of prostate cancer; and MVA-BN HER2 is for the treatment of breast cancer. Co. provides MVA-BN RSV, a treatment of bronchiolitis and pneumonia; MVA-BN HIV multiantigen, a HIV vaccine candidate; and CV-301, a cancer immunotherapy product candidate.

See profile

DK0015998017 Nasdaq Nordic Copenhagen Denmark

Provider

TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.

See profile

Other Reports on these Companies

GlobeNewsWire

Bavarian Nordics chikungunyavaccine modtager anbefaling af de amerikanske sundhedsmyndigheders rådgivningskomité (ACIP)

Bavarian Nordics chikungunyavaccine modtager anbefaling af de amerikanske sundhedsmyndigheders rådgivningskomité (ACIP) Anbefaling af den første chikungunyavaccine for personer helt ned til 12 år udvider adgangen for amerikanske rejsende til lande med udbrud eller forhøjet risiko for chikungunya. KØBENHAVN, Danmark, 16. april 2025 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at den rådgivende vaccinekomité (ACIP) hos det det amerikanske center for infektionsforebyggelse og folkesundhed (CDC) har stemt for at anbefale den viruslignende partikel (VLP)-baserede enkelt-dosis vaccine, ...

April 16, 2025 April 16, 2025 1 EN

GlobeNewsWire

Bavarian Nordic’s Chikungunya Vaccine Receives Recommendation from U.S. CDC’s Advisory Committee on Immunization Practices (ACIP)

Bavarian Nordic’s Chikungunya Vaccine Receives Recommendation from U.S. CDC’s Advisory Committee on Immunization Practices (ACIP) Recommendation of first chikungunya vaccine for persons as young as 12 years old expands access for US travelers to regions with outbreak or elevated risk of chikungunya. COPENHAGEN, Denmark, April 16, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend the virus-like particle (VLP)-based, single-dose vaccine, VIMKUNYA™ (...

April 16, 2025 April 16, 2025 1 EN

GlobeNewsWire

Correction: Beslutninger på den ordinære generalforsamling 2025 i Bavarian Nordic A/S

Correction: Beslutninger på den ordinære generalforsamling 2025 i Bavarian Nordic A/S KØBENHAVN, Danmark, 9. april 2025 – Bavarian Nordic A/S (OMX: BAVA) har i dag afholdt ordinær generalforsamling med følgende resultater: Årsrapporten for 2024 blev godkendt. Bestyrelsens forslag om, at overføre årets resultat til 2025 blev ligeledes godkendt.Vederlagsrapporten for 2024 blev ikke godkendt. Det noteres, at dette var en vejledende afstemning og at beslutningen ikke medfører konkrete konsekvenser for det afrapporterede vederlag. Bestyrelsen vil drøfte beslutningen og en redegørelse herfor vil...

April 9, 2025 April 9, 2025 1 EN

AC ENERGY CORP increases its risk exposure and slightly lowers to Neutral

AC ENERGY CORP (PH), a company active in the Alternative Electricity industry, now shows a lower overall rating. The independent financial analyst theScreener confirms the fundamental rating of 4 out of 4 stars. However, the market behaviour deterioration triggered a risk requalification, which can be thus described as moderately risky. theScreener believes that increased risk justifies the general evaluation downgrade to Neutral. As of the analysis date April 8, 2022, the closing price was PHP 8.54 and its expected value was estimated at PHP 8.53.

Free Trial

April 9, 2022 April 9, 2022 1 EN

With a more favourable environment, VUKILE PROPERTY improves to Positive

VUKILE PROPERTY (ZA), a company active in the Real Estate Holding & Development industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 4 out of 4 stars, as well as its unchanged, defensive market behaviour. The title leverages a more favourable environment and raises its general evaluation to Positive. As of the analysis date April 5, 2022, the closing price was ZAR 13.72 and its potential was estimated at ZAR 15.16.

Free Trial

April 6, 2022 April 6, 2022 1 EN

An unfavourable environment weighs on ROYAL BAFOKENG PLATINUM, which sees a downgrade to Slightly Negative

The independent financial analyst theScreener just requalified the general evaluation of ROYAL BAFOKENG PLATINUM (ZA), active in the Platinum & Precious Metals industry. As regards its fundamental valuation, the title still shows 0 out of 4 stars and its market behaviour is seen as moderately risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Slightly Negative. As of the analysis date April 5, 2022, the closing price was ZAR 159.78 and its target price was estimated at ZAR 127.50.

Free Trial

April 6, 2022 April 6, 2022 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

BAVARIAN NORDIC sees an upgrade to Slightly Positive due to a better fundamental star rating

Empowering Investors

Bavarian Nordics chikungunyavaccine modtager anbefaling af de amerikanske sundhedsmyndigheders rådgivningskomité (ACIP)

Bavarian Nordic’s Chikungunya Vaccine Receives Recommendation from U.S. CDC’s Advisory Committee on Immunization Practices (ACIP)

Correction: Beslutninger på den ordinære generalforsamling 2025 i Bavarian Nordic A/S

AC ENERGY CORP increases its risk exposure and slightly lowers to Neutral

With a more favourable environment, VUKILE PROPERTY improves to Positive

An unfavourable environment weighs on ROYAL BAFOKENG PLATINUM, which sees a downgrade to Slightly Negative

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe